SCHEMBL10244130

SCHEMBL10244130

CCn1nccc1C(C)NCCNC(=O)OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
IDH1 O75874 1/20 0.36
HTT P42858 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
GAA P10253 1/20 0.35
CTSK P43235 1/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
TSHR P16473 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243666 0.84 KMT2A (0.36) KMT2AL3MBTL1HTTGAACTSK
SCHEMBL10243922 0.78 RAB9A (0.35) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL335261 0.76 IDH1 (0.38) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL10243520 0.72 RAB9A (0.38) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL10243738 0.70 SMN1; SMN2 (0.35) MEN1KMT2ASMN1; SMN2GAASLC6A2
SCHEMBL10244577 0.68 RAB9A (0.38) RAB9AMEN1KMT2ASMN1; SMN2NPC1
Bromide SCHEMBL28277639 0.68 ALDH1A1 (0.41) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL10244285 0.68 ESR1 (0.42) SMN1; SMN2HTTSLC6A2SLC6A4SLC6A3
SCHEMBL10244235 0.68 TSHR (0.43) SMN1; SMN2NPC1L3MBTL1HTTSLC6A2
SCHEMBL10244889 0.67 CA12 (0.40) RAB9ATSHRMAPTEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RAB9A 5/4885MEN1 2456/4885KMT2A 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.